2023年8月11日

KaloCyte、盖伦机器人和Longeviti神经解决方案带来更多的支持从马里兰州资助者由山姆·霍普金斯8月11日,2023年TEDCO继续扫描本地早期公司景观科技公司可以投资,为这些公司提供资源在马里兰扎根和成长。TEDCO的记录作为一个投资者和顾问驱动器竞争各种基金申请过程,甚至在夏天的假期似乎对于许多老牌公司优先,TEDCO匹配其投资组合公司的全年创业活力突发新闻的新投资。让我们看看三个新兴巴尔的摩企业TEDCO投资500000美元为每个:KaloCyte, inc .是一家巴尔的摩公司专业创造创新人工红细胞(红血球),一个“ErythroMer系统。KaloCyte从圣路易斯到2019年秋天,搬到巴尔的摩,此后添加团队成员和建立在基础铺设在中西部地区通过工作在马里兰大学医学院的校园。2020年KaloCyte收到马里兰动量投资300000美元基金,马里兰大学系统的风险基金,促进其临床前开发的人工红细胞的替代品。ErythroMer储存和交付产品和激活减轻干在民用和军用创伤失血情况有一个致命的出血的危险。出血导致每年60000人死亡在美国,攀升至全球多达150万。防止这些死亡意味着以不同的方式考虑血液是如何存储的,运输,管理病人在紧急情况下。KaloCyte支持的承诺已收到1000万美元的赠款和投资者的资金,而今年TEDCO投入500000美元国家小企业信贷计划(SSBCI)。盖伦机器人,在巴尔的摩城市Pigtown地区创新中心也接到TEDCO投资500000美元的种子基金进一步发展其手术机器人平台。 The Laboratory of Computational Sensing and Robotics at Johns Hopkins University was the research base of the technology that was commercialized to become Galen Robotics, licensing technology developed by Russell Taylor, the lab’s director. Galen originally based its development team in Silicon Valley, but relocated its HQ to Baltimore, tapping student talent and funding including the Johns Hopkins Technology Ventures Cohen Translational Engineering Fund to move forward. The company uses assistive technology in the operating room to improve the human-machine interface in surgery and bring innovative techniques with high patient benefit to unserved markets. Its assistive technology improves workflow for surgeons in the operating process through mechanical stability and ergonomic improvements. Galen has defined key areas of emphasis including microsurgery, digital surgery, and robotic surgery–surgical robotic technologies that have expanded in use but left gaps in access. Surgical robotics has been utilized by healthcare companies to maximize potential reimbursement, but Galen’s leadership see the potential for much farther-reaching uses of assistive technologies and techniques. The American Head and Neck Society gave Galen Robotics CEO Bruce Lichorowic the Gold Shark Tank Award after the conference’s Shark Tank competition in 2023, where Galen competed against two other companies with potential to advance head and neck procedures. Also this summer, the company achieved a significant milestone with de novo clearance for its digital surgical assistant for ENT operations, part of its “digital-surgery-as-a-service” platform. Finally, Longeviti Neuro Solutions of Hunt Valley received a $500,000 investment from TEDCO’s Venture Funds . Longeviti focuses on advanced solutions for complex brain surgeries, aiming to restore anatomical normalcy while implementing innovative functional neurotechnology. Longeviti was born of a partnership with Johns Hopkins and produced several implants under the ClearFit brand for post-operative restoration of anatomical normalcy. Their low-profile intracranial device platform has achieved multiple FDA clearances including for the InvisiShunt allowing for draining of fluids from the brain. TEDCO’s half-million dollar investment in Longeviti through the State Small Business Credit Initiative adds to the organization’s previous $100,000 Maryland Innovation Initiative, combining with other funds the company has raised to expand its work in functional neurosurgery, neuro reconstruction, neuromodulation, and neurovascular surgery.